Taken together, this study reveals for the first time that Apatinib exerts anti-leukemia activity in several in vitro and in vivo preclinical models of acute lymphoblastic leukemia, likely through inhibiting VEGFR2-mediated signaling pathways, and suggests potential benefits and clinical application of Apatinib in the treatment of ALL patients. The gene discussed is KDR; the disease is leukemia.